Clinical Oncology - Issue 4/2023
Editorial
Original Articles
281
Study of KDM1A and VEGF changes as the responsible genes in the angiogenesis of breast cancer
N. Hashemi, M. Kavousi, F. Jamshidian
287
Neurobiology of multiple myeloma and its therapeutical use – results of the pilot study with a control arm
P. Kotouček, R. Enright, S. Gregor Sorgerová, Ľ. Hunáková, V. Chlebcová, D. Cholujová, J. Jakubíková, B. Mravec, E. Naništová, Ľ. Paneková, J. Sedlák
300
Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
S. Al-Samsam, J. Bartoš, V. Šámal, J. Dvořák, H. Kolářová, I. Richter
307
How patients can help us be even better doctors – educational leaflet “Before I go to the doctor”
M. Světlák, V. Šnajdrová, K. Fialová
Case Reports
314
Ewing‘s sarcoma of the urinary bladder – the urologic and pathologic differential diagnosis and current therapeutic options
M. Král, D. Kurfúrstová, I. Hartmann, H. Študentová, J. Škarda
320
Therapy of Castleman’s disease with siltuximab – case report and review of literature
Z. Adam, D. Zeman, A. Chodacki, L. Pour, T. Horváth, P. Benda, Z. Adamová, M. Krejčí, M. Tomíška, I. Boichuk, Z. Král
Reviews
268
273
Circulating free DNA and its potential in the diagnostics and therapy of malignant lymphoma
S. Hricko, V.- Navrkalová, A. Janíková
Reports from the literature
Various
Clinical Oncology
2023 Issue 4
Most read in this issue
- Enzalutamide and abiraterone in the treatment of patients with metastatic castration-resistant prostate cancer treated previously with chemotherapy
- Circulating free DNA and its potential in the diagnostics and therapy of malignant lymphoma
- Therapy of Castleman’s disease with siltuximab – case report and review of literature
- Pět P tuzemské onkologie – pochvala, podpora, polemika, pochybnosti, poklesky